RE:RE:RE:On TV With zero serious adverse effects attributed to the treatment after 60 patients treated, with the lower price tag (presumably), with the ease of administration (one or two treatments that can be delivered by a urologist), and with unrivalled long term efficacy compared to approved treatments (likely more than double that of Keytruda) it is difficult to imagine that
TLD1433 PDT is not on the way to becoming the preferred treatment for
BCG-unresponsive high grade NMIBC.
In the most recent
MD&A Theralase modestly notes:
"In 2016, Kamat et al. stated in the
Journal of Clinical Oncology that the International Bladder Cancer Group (“
IBCG”) recommended that,
“Single-arm designs may be relevant for the BCG-unresponsive population. Here, a clinically meaningful initial complete response rate (for carcinoma in situ) or recurrence-free rate (for papillary tumors) of at leastIn 2016, Kamat et al. stated in the Journal of Clinical Oncology that the International Bladder Cancer Group (“IBCG”) recommended that, “Single-arm designs may be relevant for the BCG-unresponsive population. Here, a clinically meaningful initial complete response rate (for carcinoma in situ) or recurrence-free rate (for papillary tumors) of at least
50% at 6 months, 30% at 12 months, and 25% at 18 months is recommended.”
The interim clinical data presented below meets or exceeds these IBCG guidelines."
TLD1433 PDT so far has 53% at 6 months, 36% at 12 months, and 33% at 15 months and is getting better continuously.
99942Apophis wrote: I am not medically knowledgeable but I do know that with big pharmas they tend to have an abundance of Adverse Effects and high costs.
Theralase's treatment remains in my opinion as very attractive to the destruction of cancer. Question still remains how many of the big Pharmaceuticals will want to team up in a combo to Theralase with their current treatments and also down the road as a combination treatment in their future vaccine?